These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 28193854)

  • 1. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy.
    Woo CJ; Maier VK; Davey R; Brennan J; Li G; Brothers J; Schwartz B; Gordo S; Kasper A; Okamoto TR; Johansson HE; Mandefro B; Sareen D; Bialek P; Chau BN; Bhat B; Bullough D; Barsoum J
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1509-E1518. PubMed ID: 28193854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
    Kannan A; Jiang X; He L; Ahmad S; Gangwani L
    Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Variability in the Survival Motor Neuron Genes (
    Butchbach MER
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
    Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
    Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
    Tisdale S; Pellizzoni L
    J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
    Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
    Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy.
    Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH
    Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
    Shababi M; Glascock J; Lorson CL
    Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
    Zhang ML; Lorson CL; Androphy EJ; Zhou J
    Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells.
    Grzeschik SM; Ganta M; Prior TW; Heavlin WD; Wang CH
    Ann Neurol; 2005 Aug; 58(2):194-202. PubMed ID: 16049920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
    Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
    Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges.
    Haque US; Yokota T
    Genes (Basel); 2024 Jul; 15(8):. PubMed ID: 39202360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of Patient-Identified Plasma Biomarkers in SMNĪ”7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.